Time To Inject Some Contrast into the Nephrotoxicity Debate

Iodinated contrast media have long been feared for causing contrast-induced AKI (CI-AKI), a concern rooted in early reports with high-osmolar agents. Experimental data suggest potential nephrotoxic mechanisms, yet clinical evidence from older uncontrolled studies was confounded by comorbidities and procedural risks. Contemporary propensity-matched and controlled analyses consistently show that modern low-osmolar and isoosmolar contrast agents (mostly intravenously administered) uncommonly cause true nephrotoxicity, even among high-risk populations, such as patients with advanced CKD, AKI, or critical illness. Large randomized trials, including the Prevention of Serious Adverse Events Following Angiography trial, found no difference in outcomes between sodium bicarbonate and isotonic saline hydration as preventive strategies, nor N -acetylcysteine administration, and highlighted risks like fluid overload. Persistent fear of CI-AKI has fueled renalism: unnecessary avoidance or delay of essential imaging, leading to worse outcomes. Current consensus emphasizes individualized care-avoiding hypovolemia, limiting contrast dose, and withholding nephrotoxins only in severe kidney impairment. A balanced, evidence-based approach should replace outdated caution. For decades, clinicians have approached iodinated contrast media with excessive caution over CI-AKI. This concern originated in the mid-20th century when a seminal 1954 case report described acute renal failure in a patient with myeloma after injection of a high-osmolar contrast agent. Early contrast formulations indeed had nephrotoxic effects via intense renal vasoconstriction, osmotic diuresis, and direct tubular injury. By the 1980s, any AKI after contrast exposure was broadly labeled CI-AKI, typically defined by a postprocedure increase in serum creatinine (>0.5 mg/dl or >25%) in the absence of other causes. Transition to safer low-osmolar and isoosmolar agents in the late 1980s appears to have been a pivotal step, with other factors likely contributing to the temporal decline in CI-AKI incidence. These include refinement of AKI definitions, improvements in preventive measures (avoiding hypovolemia and suspension of nephrotoxic medications), reduction in the amount of injected contrast, more cautious patient selection, and overall improvements in the management of the underlying conditions for which contrast is administered ( e.g ., acute coronary syndromes and surgical and perioperative care). Nevertheless, the historical fear of CI-AKI has persisted, often disproportionate to modern evidence, sometimes leading to avoidance of necessary diagnostic imaging. This perspective reexamines the nephrotoxicity debate in light of current knowledge, aiming to replace outdated dogma with a balanced, evidence-based approach that prioritizes patient outcomes over unfounded fears.